article thumbnail

Johnson and Johnson to Acquire Shockwave Medical

DAIC

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets. Cardiovascular intervention is one of the fastest-growing global medtech markets, with significant unmet patient need.

article thumbnail

Johnson and Johnson Completes Acquisition of Shockwave Medical

DAIC

This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. We are excited to begin collaborating directly with the Shockwave team and look forward to a bright future together.”

article thumbnail

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte Image Guided Crossing and Re-Entry Catheter System

DAIC

Getty Images milla1cf Fri, 04/12/2024 - 20:55 April 12, 2024 — Simpson Interventions, Inc. , Food and Drug Administration ( FDA ).

article thumbnail

EuroPCR 2024 Highlights

Cardiology Update

EuroPCR is the annual official congress of the European Association of Percutaneous Cardiovascular Interventions (EACPI). EuroPCR 2024 was held 14-17 May in Paris, France. In this episode Dr. Chadi Alraies discusses the top 10 sessions from EuroPCR 2024.

article thumbnail

N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery?

Journal of Cardiovascular Pharmacology

No abstract available

article thumbnail

What Are the Implications of Choosing a TAVR-First Strategy in the Lifetime Management of Aortic Stenosis?: A Critical Review of TAVR-Explant- and Redo-TAVR

Circulation: Cardiovascular Interventions

Circulation: Cardiovascular Interventions, Ahead of Print. Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many.

TAVR 73
article thumbnail

Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right?Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

European Journal of Heart Failure

While medical therapy for right-sided heart failure is limited, treatment options for tricuspid regurgitation include surgery and, based on recent developments, several transcatheter interventions.